Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1237-1245

  Home, Philip D ^a   Shen, Chunduo ^b   Hasan, Mohammad I ^c   Latif, Zafar A ^d   Chen, Jian Wen ^b   Gálvez, Guillermo González ^e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Novo Nordisk FemCare AG   (Switzerland)

^c Miracles Diabetic Institute Pakistan   (Pakistan)

^d Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

^e Instituto Jalisciense de Investigacion en Diabetes y Obesidad   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUALITY OF LIFE; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84899070938     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2413     Document Type: Article

References (33)

1. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet 1999;354:602]. Lancet 1998;352:837-853
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
4. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012 (Pubitemid 29254858)
5. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336 (Pubitemid 41079631)
6. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26- week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274 (Pubitemid 44125921)
7. Raskin P, Allen E, Hollander P, et al.; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265 (Pubitemid 40170923)
8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086 (Pubitemid 37339502)
9. Khunti K, Caputo S, Damci T, et al.; on behalf of the SOLVE Study Group. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 25 July 2012 [Epub ahead of print]
10. Dornhorst A, Lüddeke HJ, Sreenan S, et al.; PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:659-665 (Pubitemid 351348041)
11. Schreiber SA, Ferlinz K, Haak T. The longterm efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008;10:121-127 (Pubitemid 351230289)
12. Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011;94:352-363
13. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013;36:1779-1788
14. International Diabetes Federation. Clinical guidelines task force. Global guidelines for type 2 diabetes [Internet], 2012. Brussels, Belgium, International Diabetes Federation. Available from http://www.idf.org/sites/ default/files/IDF%20T2DM%20Guideline.pdf. Accessed 20 August 2013
15. Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycemic control in insulinusing adults with type 2 diabetes. Diabetes Care 2000;23:273-277 (Pubitemid 30131729)
16. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health 2005;5:36
17. Janghorbani M, Amini M. Patterns and predictors of long-term glycemic control in patients with type 2 diabetes. ISRN Endocrinol 2012;2012:526824
18. Fujita N, Tsujii S, Kuwata H, et al. Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy. J Diabetes Invest 2012;3:164-169
19. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complications 2010;24:84-89
20. Valensi P, Shaban J, Benroubi M, et al.; IMPROVE Study Expert Panel. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study. Curr Med Res Opin 2013;29:601-609
21. Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011;94:364-370
22. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27:309-317
23. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. Int J Clin Pract 2011;65:602-612
24. Aschner P, Katzeff HL, Guo H, et al.; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-261
25. Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group. Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. Endocr Pract 2013;19:462-470
26. Home P, Malek R, Prusty V, Latif Z, Haddad J. Impact of insulin detemir on weight change in relation to baseline BMI: observations from the A1chieve study. Late-breaking abstract presented at the 73rd Annual Meeting of the American Diabetes Association, 21-25 June 2013, McCormick Place, Chicago, IL (poster 963-P)
27. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
28. Freemantle N, Balkau B, Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013;15:1120-1127
29. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care 2012;35:495-497
30. ChanWB, Chan JC, Chow CC, et al. Glycaemic control in type 2 diabetes: the impact of body weight, beta-cell function and patient education. QJM 2000;93:183-190 (Pubitemid 30128706)
31. O'Connor PJ, Crabtree BF, Abourizk NN. Longitudinal study of a diabetes education and care intervention: predictors of improved glycemic control. J Am Board Fam Pract 1992;5:381-387
32. Home P, Gálvez GG, Malek R, et al. Short and long-term cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes. Value Health 2013;16:A164
33. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990